Recommendations for the treatment of factor VIII inhibitors
| Autor: | F. E. Preston, Christopher A. Ludlam, Charles R. M. Hay, B. T. Colvin, F. G. H. Hill |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
congenital
hereditary and neonatal diseases and abnormalities medicine.medical_specialty Chemotherapy business.industry medicine.medical_treatment Autoantibody Immunosuppression Hematology General Medicine Guideline Bethesda unit medicine.disease Haemophilia Surgery hemic and lymphatic diseases Internal medicine Coagulopathy Medicine Anamnestic response business |
| Zdroj: | Blood Coagulation & Fibrinolysis. 7:134-138 |
| ISSN: | 0957-5235 |
| DOI: | 10.1097/00001721-199603000-00005 |
| Popis: | A strategy is described for the initial detection, management and elimination of factor VIII inhibitors arising in patients with congenital and acquired haemophilia A. It is suggested that children with severe haemophilia A should be screened every 3 months up to the age of 10 years for inhibitors using the Bethesda method. Factor VIII inhibitors arising in these patients should be abolished using immune-tolerance induction wherever possible. Such regimes should be started as early as possible, preferably when the inhibitor titre is < 10 Bethesda Units (BU)/ml, and should not be interrupted. High-intensity regimes are recommended for patients whose inhibitors exceed 10 BU. Autoantibodies to factor VIII giving rise to acquired haemophilia should be abolished using high-dose immunoglobulin or conventional immunosuppression. The choice of haemostatic agent for the treatment of severe bleeding should be based upon the clinical circumstances and the current inhibitor value, measured using both human and porcine factor VIII in the Bethesda assay. The past anamnestic response should also be considered when choosing treatment for minor bleeding episodes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|